Directed To Deliver
Voyager is advancing early-stage programs powered by proprietary, next-generation AAV capsids to deliver innovative gene therapies using various payloads. The pipeline supports the Company’s strategic vision for developing best-in-class treatments by focusing on validated targets, following efficient pathways to preclinical and clinical proof of concept, and seeking opportunities to provide meaningful therapeutic benefit to patients in areas of significant unmet need.
Monogenic ALS (SOD1)
Spinal Muscular Atrophy
HER2+ Brain Metastases
*Parkinson’s Disease, Lewy Body Dementia, Gaucher Disease
Voyager is partnering with Neurocrine Biosciences on a preclinical Friedreich’s Ataxia (FA) program and two undisclosed discovery programs. Voyager has an option to co-develop/co-commercialize the FA program in the U.S. or to grant Neurocrine global commercial rights.
Here we have gathered resources for patients and caregivers looking to better understand the diseases we seek to treat. If you are a patient or caregiver, please feel free to contact Voyager with questions: firstname.lastname@example.org